Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- KRRO -76.4% (also provides updates on KRRO-110; also workforce reduction and resignation of Chief Medical Officer), ARDT -29.7%, WBTN -25.7% (also to develop slate of animated projects with Warner Bros. Animation), GAMB -19.3%, IBTA -18.8%, KLC -17%, PSFE -14.5%, ABSI -11.6%, DLO -11.2%, CCRN -9.5%, BITF -9.1%, EGAN -7%, HTFL -5.8%, ASND -5.6%, KDK -5.5%, ALVO -5.2%, ARMP -4.5%, NESR -4.5%, HZO -4.2%, DIS -3.5%, UAMY -3.3%, LB -2.5%, FLUT -2.3%, EPC -2.3%, SVCO -1.5%, AVR -1%, LAC -1%
Other news:
- BTDR -15.8% ($400 mln convertible notes proposed private placement)
- DAWN -13.9% (Day One Biopharmaceuticals (DAWN) to acquire Mersana Therapeutics for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to $30.25 per share)
- CTEV -10.8% (prices offering by selling stockholders of 1.5 mln shares of common stock at $51.50 per share)
- NFE -8.6% (to delay 10-Q filing)
- ANNX -6.7% (prices $75 million public offering consisting of common stock and pre-funded warrants)
- IVA -3.7% (files for $125 mln ADS offering)
- NGNE -3.5% (interim data in pediatric cohort from NGN-401 gene therapy trial)
- CTRI -2.8% (launches $160 mln stock offering; Icahn Partners to purchase $75 mln of shares in concurrent private placement)
- IONS -2.8% (prices $700 mln convertible notes to refinance 2026 debt)
- NKTR -2.2% (files mixed securities shelf offering)
- INGM -1.3% (25.5 mln share offering by selling shareholders)
- ALTS -0.9% (to delay 10-Q filing)